Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Radioactive cesium ions, most notably the isotope Cesium-137, are hazardous radionuclides produced during nuclear fission in reactors or weapons. Due to their chemical similarity to potassium, these ions are rapidly absorbed by the human body and distributed throughout soft tissues, particularly muscle and liver. Once internalized, they emit ionizing radiation in the form of beta particles and gamma rays, which can lead to significant cellular damage and an increased long-term risk of cancer. In clinical toxicology, these ions are the primary target for decorporation therapy using agents like Prussian Blue (ferric hexacyanoferrate). Prussian Blue acts as a non-absorbable ion exchanger in the gut, binding the cesium ions to prevent their reabsorption through the enterohepatic cycle and significantly reducing their biological half-life.
Ion exchange and sequestration within the gastrointestinal tract to interrupt enterohepatic circulation and enhance fecal elimination.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Radioactive cesium ion (Cs-137).